Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19.
Elizabeth E ZumbrunChengzi I KakuLukas DillingerSamantha E ZakAna I KuehneRussel R BakkenJeffrey W KoehlerKorey L DelpChristopher P StefanRaina KumarJeffrey R KugelmanAlicia M MoreauXiankun ZengJohn M DyeAndrew S HerbertKristin NarayanLaura M WalkerPublished in: Antimicrobial agents and chemotherapy (2022)
Adintrevimab is a human immunoglobulin G1 monoclonal antibody engineered to have broad neutralization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and other SARS-like coronaviruses with pandemic potential. In both Syrian golden hamster and rhesus macaque models, prophylactic administration of a single dose of adintrevimab provided protection against SARS-CoV-2/WA1/2020 infection in a dose-dependent manner, as measured by significant reductions in lung viral load and virus-induced lung pathology, and by inhibition of viral replication in the upper and lower respiratory tract.